Fibroblastenwachstumsfaktor 9
Das FGF9-Gen kodiert ein glia-aktivierenden Wachstumsfaktor. Mutationen führen zur dominantem Syndrom der multiplen Synostosen 3.
Gentests:
| Klinisch |
Untersuchungsmethoden |
Familienuntersuchung |
| Bearbeitungszeit |
5 Tage |
| Probentyp |
genomische DNS |
Verknüpfte Erkrankungen:
Referenzen:
| 1. |
Sun X et. al. (2000) Conditional inactivation of Fgf4 reveals complexity of signalling during limb bud development.
[^]
|
| 2. |
Mariani FV et. al. (2008) Genetic evidence that FGFs have an instructive role in limb proximal-distal patterning.
[^]
|
| 3. |
Miyamoto M et. al. (1993) Molecular cloning of a novel cytokine cDNA encoding the ninth member of the fibroblast growth factor family, which has a unique secretion property.
[^]
|
| 4. |
Mattei MG et. al. (1995) The human FGF9 gene maps to chromosomal region 13q11-q12.
[^]
|
| 5. |
Colvin JS et. al. (2001) Male-to-female sex reversal in mice lacking fibroblast growth factor 9.
[^]
|
| 6. |
Katoh M et al. (2005) Comparative genomics on FGF20 orthologs.
[^]
|
| 7. |
Harada M et. al. (2009) FGF9 monomer-dimer equilibrium regulates extracellular matrix affinity and tissue diffusion.
[^]
|
| 8. |
Wu XL et. al. (2009) Multiple synostoses syndrome is due to a missense mutation in exon 2 of FGF9 gene.
[^]
|
| 9. |
Barak H et al. (2012) FGF9 and FGF20 maintain the stemness of nephron progenitors in mice and man.
[^]
|
Update: 26. September 2018
